Related Experiment Video
Updated: May 21, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Breaking the tolerance for tumor: Targeting negative regulators of TLR signaling
Theodore J Standiford1, Venkateshwar G Keshamouni
1Division of Pulmonary and Critical Care Medicine; Department of Internal Medicine; University of Michigan Medical Center; Ann Arbor, MI USA.
Abstract:
Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by tumors to induce tolerance and mitigate the host immunosurveillance. Targeting these negative regulators can be a potential new immunotherapeutic strategy.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
TGF - β Signaling Pathway
